Twist Bioscience Corp. Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Twist Bioscience Corporation on October 24, 2019. The report discloses a corporate governance event regarding the Board of Directors.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial statements or performance data.
Material Changes
The Board of Directors increased its size from nine to ten members. Nicolas Barthelemy was elected to fill a newly created vacancy, effective immediately. He was appointed to serve as a Class II director until the 2020 Annual Meeting and was assigned to the Audit and Compensation Committees.
Guidance, Outlook, and Risks
The filing contains no management commentary, financial guidance, outlook, or discussion of risks and contingencies. Mr. Barthelemy will be compensated according to the Company's Non-Employee Director Compensation Policy and has entered into a standard Indemnification Agreement.
Key Facts for Investor Verification
- Nicolas Barthelemy was appointed to the Board of Directors on October 24, 2019.
- The Board size increased from nine to ten members.
- Mr. Barthelemy serves on the Audit and Compensation Committees.
- No financial data or operational metrics are included in this specific filing.